auto-fix: strip 16 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

inbox/queue/2025-07-apa-monitor-glp1-mental-health-effects.md

@@ -33,8 +33,8 @@ Key facts (from search summaries — full text access limited):
 **What I expected but didn't find:** APA clinical practice guidelines on GLP-1 prescribing or monitoring — these don't appear to exist yet as of 2026.
 
 **KB connections:**
-- [[the mental health supply gap is widening not closing]] — psychologists are now managing GLP-1-related mental health effects without training
+- the mental health supply gap is widening not closing — psychologists are now managing GLP-1-related mental health effects without training
-- [[prescription digital therapeutics failed as a business model]] — analogous: psychological community engaging with pharmaceutical interventions that cross into behavioral territory
+- prescription digital therapeutics failed as a business model — analogous: psychological community engaging with pharmaceutical interventions that cross into behavioral territory
 
 **Extraction hints:**
 - Supplementary source for the GLP-1 anhedonia claim (professional community recognition predating mainstream news)
@@ -43,6 +43,6 @@ Key facts (from search summaries — full text access limited):
 **Context:** APA Monitor is distinct from the peer-reviewed journals (Psychological Review, Journal of Consulting and Clinical Psychology); it's the professional magazine reaching 130,000+ APA members.
 
 ## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[the mental health supply gap is widening not closing]]
+PRIMARY CONNECTION: the mental health supply gap is widening not closing
 WHY ARCHIVED: APA professional community recognition establishes timeline of awareness; supplementary evidence for GLP-1 psychiatric effects claim
 EXTRACTION HINT: Use as supporting evidence for claims about GLP-1 psychiatric effects; note 9-month gap between professional and public awareness as indicator of how slowly clinical findings reach practice guidelines

inbox/queue/2026-03-lancetpsychiatry-glp1-mental-illness-swedish-cohort.md

@@ -53,8 +53,8 @@ Karolinska Institutet press coverage: "Diabetes drug Ozempic linked to better me
 
 **KB connections:**
 - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — safety profile is better than prior signals suggested
-- [[the mental health supply gap is widening not closing]] — GLP-1s addressing depression/anxiety/SUD could partially offset the supply gap through pharmacological means
+- the mental health supply gap is widening not closing — GLP-1s addressing depression/anxiety/SUD could partially offset the supply gap through pharmacological means
-- [[medical care explains only 10-20 percent of health outcomes]] — GLP-1s challenge the clean clinical/non-clinical boundary by addressing non-clinical pathways through clinical drugs
+- medical care explains only 10-20 percent of health outcomes — GLP-1s challenge the clean clinical/non-clinical boundary by addressing non-clinical pathways through clinical drugs
 - Divergence candidate: GLP-1 psychiatric safety — matched cohort (195% MDD risk) vs. within-individual (42% reduction in worsening)
 
 **Extraction hints:**

inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md

@@ -38,8 +38,8 @@ Key facts reported:
 
 **KB connections:**
 - [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the safety profile complicates the "net positive" clinical narrative
-- [[the mental health supply gap is widening not closing]] — anhedonia in GLP-1 users who lack psychiatric monitoring
+- the mental health supply gap is widening not closing — anhedonia in GLP-1 users who lack psychiatric monitoring
-- [[human needs are finite universal and stable across millennia]] — meaning and social connection as fundamental health determinants
+- human needs are finite universal and stable across millennia — meaning and social connection as fundamental health determinants
 
 **Extraction hints:**
 - Primary claim: "GLP-1-induced anhedonia is dose-dependent and resolves in most cases within weeks of dose reduction, suggesting tonic dopamine suppression rather than permanent neurological change"

inbox/queue/2026-04-30-washingtontimes-ozempic-personality-physicians-flag.md

@@ -34,9 +34,9 @@ Key facts (referenced in Session 37 musing):
 **What I expected but didn't find:** Any reported cases of permanent or irreversible anhedonia. All cases referenced suggest dose-reduction or discontinuation resolves the effect — suggesting this is a sustained pharmacological effect rather than lasting neurological damage.
 
 **KB connections:**
-- [[social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day]] — if GLP-1 reduces social appetite/engagement, this is a clinical driver of loneliness-equivalent harm
+- social isolation costs Medicare 7 billion annually and carries mortality risk equivalent to smoking 15 cigarettes per day — if GLP-1 reduces social appetite/engagement, this is a clinical driver of loneliness-equivalent harm
-- [[modernization dismantles family and community structures replacing them with market and state relationships]] — GLP-1-induced social disengagement adds pharmaceutical pressure to social connection erosion
+- modernization dismantles family and community structures replacing them with market and state relationships — GLP-1-induced social disengagement adds pharmaceutical pressure to social connection erosion
-- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — GLP-1 at therapeutic doses may treat the 10-20% (metabolic) while eroding two of the 80-90% (meaning, social connection)
+- medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate — GLP-1 at therapeutic doses may treat the 10-20% (metabolic) while eroding two of the 80-90% (meaning, social connection)
 
 **Extraction hints:**
 - Primary claim candidate: "GLP-1 therapeutic doses suppress dopaminergic reward broadly — reducing appetite for social activities, sex, and meaning-making alongside food — potentially eroding two of Belief 2's four non-clinical health determinants"

inbox/queue/2026-osmind-glp1-psychiatric-drugs-tonic-phasic.md

@@ -52,8 +52,8 @@ GLP-1 receptors are densely distributed in psychiatric-relevant brain circuits:
 
 **KB connections:**
 - [[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]] — analogous: optimizing GLP-1 dosing for weight loss may create psychiatric harm demand
-- [[the mental health supply gap is widening not closing]] — GLP-1s addressing SUD and mood could offset some of this
+- the mental health supply gap is widening not closing — GLP-1s addressing SUD and mood could offset some of this
-- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone]] — analogous structural problem: wrong professional type (primary care vs. psychiatry) optimizing the wrong metric creates unintended psychiatric harm
+- human-in-the-loop clinical AI degrades to worse-than-AI-alone — analogous structural problem: wrong professional type (primary care vs. psychiatry) optimizing the wrong metric creates unintended psychiatric harm
 
 **Extraction hints:**
 - Primary claim: "GLP-1-induced anhedonia is a tonic receptor occupancy phenomenon, not an inherent pharmacological property, resolving with dose reduction because natural GLP-1 is phasic"

inbox/queue/2026-pmc12673456-glp1-psychiatric-systematic-review.md

@@ -59,9 +59,9 @@ Systematic review of emerging evidence on psychiatric effects of GLP-1 receptor
 **What I expected but didn't find:** Any validated clinical instrument being deployed to systematically capture anhedonia in GLP-1 trials. The Snaith-Hamilton Pleasure Scale (SHAPS) exists and is validated — the absence of SHAPS in GLP-1 trials means anhedonia is invisible to clinical trial infrastructure.
 
 **KB connections:**
-- [[medical LLM benchmark performance does not translate to clinical impact]] — analogous evidence gap: lab findings (RCT, controlled) don't translate to real-world population outcomes
+- medical LLM benchmark performance does not translate to clinical impact — analogous evidence gap: lab findings (RCT, controlled) don't translate to real-world population outcomes
-- [[prescription digital therapeutics failed as a business model]] — regulatory infrastructure (FDA trial design) shapes what evidence gets collected; no tool for measuring hedonic outcomes → no regulatory pressure to address anhedonia
+- prescription digital therapeutics failed as a business model — regulatory infrastructure (FDA trial design) shapes what evidence gets collected; no tool for measuring hedonic outcomes → no regulatory pressure to address anhedonia
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history]]
+- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history
 
 **Extraction hints:**
 - Primary claim from this review: "Human dose-response data on GLP-1 psychiatric effects are absent from the literature despite mechanistic evidence that tonic receptor occupancy at therapeutic weight-loss doses suppresses dopamine signaling differently than lower psychiatric doses"

inbox/queue/2026-q1-psychopharmacology-glp1-psychiatric-review.md

@@ -48,7 +48,7 @@ Psychopharmacology Institute quarterly clinical review (Q1 2026) covering GLP-1
 
 **KB connections:**
 - [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — analogous: drug label policies carried over from non-relevant predecessors mislead clinical practice
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history]]
+- GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history
 
 **Extraction hints:**
 - Supporting evidence for: "GLP-1 suicidality warning removal (January 2026) was based on 91-RCT meta-analysis finding no signal, not because the signal was inadequately studied"